Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cathepsin E short hairpin RNA is an RNA interference (RNAi) based therapeutic agent designed to specifically silence the expression of the *CTSE* gene. Cathepsin E is an intracellular aspartic protease that plays a critical role in colorectal cancer (CRC) progression by promoting metastasis and facilitating immune evasion. The mechanism involves the ADP-ribosylation of ZNF326 and the subsequent activation of the TGF-β/SMAD signaling pathway, which drives tumor growth and suppresses anti-tumor immune responses. By delivering shRNA sequences—often via viral vectors or lipid nanoparticles—the agent triggers the sequence-specific degradation of CTSE mRNA, thereby reducing protein levels and potentially inhibiting the malignant phenotype of CRC cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cathepsin E short hairpin RNA.